8th Annual Business Development Forum
and Networking Reception

Innovators + Generics: The Integration of the
Pharma Business Model


Monday, March 15, 2010
1:15pm - 4:15 pm, Empire Room
Waldorf-Astoria Hotel, NYC

Networking Reception:
4:30pm - 6:00 pm, Peacock Alley private dining room

Member: $199; Non-Member: $599
(includes education program and networking reception)


Program Description:

The difference between innovator and generic companies has become less defined as these companies implement strategies to grow and diversify their global presence. Patent expiries, healthcare reform, price controls in major markets, and a reduced novel product pipeline have prompted innovators to enter collaborations with generic companies to broaden product portfolios and increase presence in emerging markets. At the same time, generic companies have been investing in R&D and participating in the innovator arena. Leading pharmaceutical executives will discuss the trend towards diversifying, their decision-making process, key business factors and insights into their
company’s strategies.

Topics & Speakers: Learn more >

Is the Grass Greener on the Other Side? Trends Toward Diversifying into Adjacent Spaces
Kimberly A. Wagner, PhD, Sr. Partner & Managing Director,
The Boston Consulting Group, Inc.

Pfizer's Established Products Business Unit: The Inside Story
Kelvin Cooper, Sr. Vice President of Portfolio Development for the
Established Products Unit, Pfizer Inc.

The Blurred Line Between Innovator and Generic Pharma:
Case Studies and Implications
Amit M. Patel, Sr. Vice President & Head, North America Generics,
Dr. Reddy's Laboratories

Achieving Harmony: Branded & Generics Dual Identity
Stephen Auten, Vice President & General Patent Counsel,
Sandoz, Inc., a Novartis Company

Achieving Growth through Redefining Opportunities in
the Generics Market
Ira Baeringer, Director, Life Cycle Management & Generics,
sanofi-aventis